中英文說明丨艾美捷InVivoMAb 抗小鼠NK1.1
The PK136 monoclonal antibody reacts with mouse NK1.1 also known as CD161b/CD161c, KLRB1, NKR-P1A and Ly-55. NK1.1 is a type II integral membrane glycoprotein with a C-type lectin domain and is encoded by the Klrb1c/NKR-P1C gene. NK1.1 plays roles in NK cell activation and differentiation, IFN-γ production, cytotoxic granule release, and is thought to be involved in the generation of Th2 cells. NK1.1 is predominantly expressed as a disulfide-linked homodimer on NK cells however, it is also expressed on NK-T cells, a rare population of T lymphocytes. NK 1.1 is only expressed by C57BL/6, FVB/N, and NZB strains of mice and not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129 strains.
?
Isotype?Mouse IgG2a, κ
Recommended Isotype Control(s)?InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer?InVivoPure pH 7.0 Dilution Buffer
Immunogen?Mouse spleen and bone marrow cells enriched for NK1+ cells
Reported Applications?in vivo NK cell depletion
Flow cytometry
Formulation?PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin?<2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity?>95%
Determined by SDS-PAGE
Sterility?0.2 μM filtered
Production?Purified from tissue culture supernatant in an animal free facility
Purification?Protein A
RRID?AB_1107737
Molecular Weight?150 kDa
Storage?The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
?
PK136單克隆抗體與小鼠NK1.1反應(yīng),也稱為CD161b / CD161c,KLRB1,NKR-P1A和Ly-55。NK1.1是一種具有C型凝集素結(jié)構(gòu)域的II型整合膜糖蛋白,由Klrb1c/NKR-P1C基因編碼。NK1.1在NK細胞活化和分化,IFN-γ產(chǎn)生,細胞毒性顆粒釋放中起作用,并被認(rèn)為參與Th2細胞的產(chǎn)生。NK1.1主要在NK細胞上表達為二硫鍵連接的同源二聚體,然而,它也在NK-T細胞上表達,NK-T細胞是一種罕見的T淋巴細胞群。NK 1.1僅由小鼠的C57BL / 6,F(xiàn)VB / N和NZB菌株表達,而不是AKR,BALB / c,CBA / J,C3H,DBA / 1,DBA / 2,NOD,SJL和129株表達。
?

?
艾美捷InVivoMAb抗小鼠NK1.1#BE0036基本參數(shù):
同種型?小鼠IgG2a, κ
推薦的同種型對照?體內(nèi)MAb小鼠IgG2a同種型對照,特異性未知
推薦的稀釋緩沖液?體內(nèi)純?pH 7.0 稀釋緩沖液
免疫原?富含NK1+細胞的小鼠脾臟和骨髓細胞
報告的應(yīng)用程序?體內(nèi)NK細胞去除
流式細胞術(shù)
配方?PBS,pH 7.0
不含穩(wěn)定劑或防腐劑
內(nèi)毒素?<2EU/mg (<0.002EU/μg)
通過LAL凝膠凝血測定法測定
純度?>95%
由?SDS-PAGE 決定
無?菌?0.2 μM 過濾
生產(chǎn)?從無動物設(shè)施中的組織培養(yǎng)上清液中純化
純化?蛋白A
里德?AB_1107737
分子量?150 千達
存儲?抗體溶液應(yīng)以4°C的儲備濃度儲存。 不要凍結(jié)。
?
InVivoMAb抗小鼠NK1.1部分文獻引用:
in vivo NK cell depletion
Ghasemi, R., et al. (2016). "Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy" Nat Commun 7: 12878.
in vivo NK cell depletion, Flow Cytometry
Maltez, V. I., et al. (2015). "Inflammasomes Coordinate Pyroptosis and Natural Killer Cell Cytotoxicity to Clear Infection by a Ubiquitous Environmental Bacterium" Immunity 43(5): 987-997.
in vivo NK cell depletion, Flow Cytometry
Wensveen, F. M., et al. (2015). "NK cells link obesity-induced adipose stress to inflammation and insulin resistance" Nat Immunol 16(4): 376-385.
in vivo NK cell depletion
Yamada, D. H., et al. (2015). "Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection" Immunity 42(2): 379-390.